Hepatocardial syndrome in patients after ST-segment elevation myocardial infarction. GEFEST study
Russian Journal of Preventive Medicine · 05.08.2026 · 29 (7) · 90
DOI: 10.17116/profmed20262907190 ↗Kurz gefasst
Fachartikel in der Zeitschrift Russian Journal of Preventive Medicine, erschienen am 05.08.2026. Verfasst von I.A. Zolotovskaia und 3 weiteren Autor:innen. Die Arbeit nennt 21 Literaturangaben.
Abstract (Originalsprache)
Objective. To investigate the clinical and laboratory changes, specifically focusing on liver function tests, echocardiographic parameters, as well as cognitive and emotional status, and to assess the incidence of cardiovascular events over a period of 12 months in elderly patients diagnosed with hepatocardial syndrome after ST-elevation myocardial infarction (STEMI), in the settings of standard cardiac therapy. Materials and methods. A prospective cohort comparative study was conducted, involving 537 patients aged 60 years or older (median age 68 [64; 73] years), who were evaluated no later than 6 months after a STEMI event. Two comparable groups were established through stratified selection based on sex, age, left ventricular ejection fraction (LVEF), and the grade of hepatic dysfunction: the main study group (n=269) and the control group (n=268). Patients in the main study group received ademetionine in addition to standard cardiac therapy, while those in the control group received standard therapy only. The primary endpoints included changes in alanine aminotransferase (ALAT), gamma-glutamyl transpeptidase (GGTP), and albumin levels at 6 months. Secondary endpoints included changes in LVEF, validated questionnaires scores (Montreal Cognitive Assessment Scale, Hospital Anxiety and Depression Scale, and Multidimensional Assessment of Fatigue), and the frequency of recurrent myocardial infarction, stroke, and cardiovascular mortality within 12 months. Statistical analyses were performed using the t-test, Mann—Whitney test, Pearson’s χ² test, and Bonferroni-corrected Cox regression for primary outcomes (p
Zitieren
APA
Zolotovskaia, I., Duplyakov, D., Shatskaia, P., & Konstantinov, D. (2026). Hepatocardial syndrome in patients after ST-segment elevation myocardial infarction. GEFEST study. Russian Journal of Preventive Medicine, 29(7), 90. https://doi.org/10.17116/profmed20262907190
Vancouver
Zolotovskaia I, Duplyakov D, Shatskaia P, Konstantinov D. Hepatocardial syndrome in patients after ST-segment elevation myocardial infarction. GEFEST study. Russian Journal of Preventive Medicine. 2026;29(7):90. doi:10.17116/profmed20262907190
BibTeX
@article{Zolotovskaia2026,
author = {Zolotovskaia, I.A. and Duplyakov, D.V. and Shatskaia, P.R. and Konstantinov, D.Yu.},
title = {Hepatocardial syndrome in patients after ST-segment elevation myocardial infarction. GEFEST study},
journal = {Russian Journal of Preventive Medicine},
year = {2026},
volume = {29},
number = {7},
pages = {90},
doi = {10.17116/profmed20262907190}
}
EUVIMED